ACET Insider Trading
Insider Ownership Percentage: 7.80%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Adicet Bio Share Price & Price History
Current Price: $0.62
Price Change: ▲ Price Increase of +0.007 (1.14%)
As of 07/3/2025 04:56 PM ET
Adicet Bio Insider Trading History
Adicet Bio Institutional Trading History
Data available starting January 2016
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.
Read More on Adicet Bio
Volume
545,982 shs
Average Volume
655,306 shs
Market Capitalization
$51.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.62
Who are the company insiders with the largest holdings of Adicet Bio?